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Background:  Kawasaki disease (KD) is an acute vasculitis that can result in endothelial dysfunction and coronary artery aneurysms 
(CAA) in 25% of untreated children. Our previous studies suggests Endothelial-to-mesenchymal transition (EndoMT) is involved in KD 
patients with CAA, evidenced by positive staining for connective tissue growth factor (CTGF) and EndoMT markers such as alpha smooth 
muscle cell actin-α. However, little is known about mechanisms mediating EndoMT in KD. In this study, we investigated the molecular basis 
underlying microRNA (miRNA) regulation of CTGF and the consequent EndoMT in KD pathogenesis.
methods:  Sera from healthy children (n=6), KD patients with (n=18) or without (n=7) CAA were used to treat human umbilical vein 
endothelial cells. Several cardiovascular disease-associated miRNAs, CTGF and EndoMT markers were quantified by realtime-PCR 
and Western blotting. Bioinformatic analysis was used to predict transcription factors for miRNA induction and targets. Gain- and loss-of-
function experiments were performed to dissect the molecular regulation of miRNA and CTGF.
results:  Compared to healthy controls, sera from acute KD patients without CAA was associated with decreased miR-483 and increased 
CTGF and EndoMT markers in ECs. The effect was even more prominent with CAA+ KD sera. Bioinformatic analysis suggested that miR-
483 could directly target the 3’untranslated region of CTGF mRNA, which was validated by luciferase assays. miR-483 was shown to be 
transcriptionally induced by Kruppel-like factor 4 (KLF4), a transcription factor known to maintain EC lineage. Overexpression of KLF4 or 
pre-miR-483 suppressed, whereas anti-miR-483 enhanced CTGF expression. Furthermore, atorvastatin (currently being tested in a KD 
clinical trial) induced KLF4-miR-483 and suppressed CTGF and EndoMT in ECs.
conclusion:  KD sera suppress the anti-fibrotic KLF4-miR-483 axis in EC leading to increased CTGF and EndoMT. Such a mechanism 
may contribute to CAA in KD patients. Pharmacological intervention using statins may be beneficial, partially through the restoration of 
KLF4-miR-483 expression.
